for investors

Investors

corporate profile
Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
stock
snapshot
Additional stock info »
08.8.2020 | 4:18 AM EDT
Copyright West LLC. Minimum 15 minutes delayed.
Press Releases
Aug 05, 2020
Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
Jul 23, 2020
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
Jul 13, 2020
Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
View all news »
Events & Presentations
Aug 6, 2020 12:00 PM EDT
Ovid Therapeutics Inc at William Blair Biotech Focus Conference 2020
Jul 13, 2020 8:15 AM EDT
OV101 Angelini License Agreement Conference Call
Jun 17, 2020 1:00 PM EDT
Soticlestat Educational Webinar
View all events and presentations »
Latest Corporate Presentation Get the Ovid primer— download our latest corporate presentation for investors.
More information is coming soon.
Explore the Ovid Pipeline The Ovid pipeline includes several candidates that would potentially be the first to make a meaningful impact in the lives of individuals with rare neurological conditions. View our pipeline »
Get Investor Updates Have the latest on the BOLD happenings at Ovid, from clinical trial endpoint and data announcements to corporate news, sent right to your inbox. Sign up now »
latest updates